JAK2 and Hodgkins lymphoma: ODZ10117 did not significantly inhibit the JAK family of tyrosine kinases, including JAK1, JAK2, JAK3, and TYK2, in breast cancer cells and Hodgkin’s lymphoma cells (Figure 5 and Supplementary Figure S10B).